Compare BNC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNC | VCRE |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 271.7M |
| IPO Year | 2010 | 2026 |
| Metric | BNC | VCRE |
|---|---|---|
| Price | $3.61 | $10.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.37 |
| AVG Volume (30 Days) | ★ 739.1K | 17.0K |
| Earning Date | 12-14-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,581,968.00 | N/A |
| Revenue This Year | $27.15 | $38.94 |
| Revenue Next Year | $6.70 | $694.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $1.84 | $7.88 |
| 52 Week High | $7.72 | $14.01 |
| Indicator | BNC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 54.19 |
| Support Level | $2.73 | $10.56 |
| Resistance Level | $4.14 | $11.88 |
| Average True Range (ATR) | 0.26 | 0.42 |
| MACD | -0.14 | 0.12 |
| Stochastic Oscillator | 0.66 | 63.71 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.